These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10852092)

  • 21. Carnitine deficiency: Risk factors and incidence in children with epilepsy.
    Fukuda M; Kawabe M; Takehara M; Iwano S; Kuwabara K; Kikuchi C; Wakamoto H; Morimoto T; Suzuki Y; Ishii E
    Brain Dev; 2015 Sep; 37(8):790-6. PubMed ID: 25547040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
    Mock CM; Schwetschenau KH
    Am J Health Syst Pharm; 2012 Jan; 69(1):35-9. PubMed ID: 22180549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carnitine deficiency associated with anticonvulsant therapy.
    Rodriguez-Segade S; de la Peña CA; Tutor JC; Paz JM; Fernandez MP; Rozas I; Del Río R
    Clin Chim Acta; 1989 May; 181(2):175-81. PubMed ID: 2500272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levocarnitine for the Treatment of Valproic Acid-Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center.
    Glatstein M; Bonifacio Rino P; de Pinho S; Scolnik D; Pivko-Levi D; Hoyte C
    Am J Ther; 2019; 26(3):e344-e349. PubMed ID: 29232283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation.
    Sugimoto T; Nishida N; Murakami K; Woo M; Sakane Y; Yasuhara A; Shuto H; Hatanaka T; Kobayashi Y
    Jpn J Psychiatry Neurol; 1990 Jun; 44(2):387-8. PubMed ID: 2124297
    [No Abstract]   [Full Text] [Related]  

  • 28. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence?
    Zelnik N; Fridkis I; Gruener N
    Acta Paediatr; 1995 Jan; 84(1):93-5. PubMed ID: 7734910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy.
    Qiliang L; Wenqi S; Hong J
    Indian Pediatr; 2018 Mar; 55(3):222-224. PubMed ID: 29629695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of L-carnitine treatment for valproate-induced hepatotoxicity.
    Bohan TP; Helton E; McDonald I; König S; Gazitt S; Sugimoto T; Scheffner D; Cusmano L; Li S; Koch G
    Neurology; 2001 May; 56(10):1405-9. PubMed ID: 11376200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
    Yokoyama S; Yasui-Furukori N; Nakagami T; Miyazaki K; Ishioka M; Tarakita N; Kubo K; Sugawara N; Shimoda K
    Ther Drug Monit; 2020 Oct; 42(5):766-770. PubMed ID: 32482992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypsarrhythmia and spasms resolution after Valproic acid discontinuation in an infantile spasm patient.
    Alsallumi MS
    Neurosciences (Riyadh); 2019 Oct; 24(4):311-314. PubMed ID: 31872811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
    Coppola G; Epifanio G; Auricchio G; Federico RR; Resicato G; Pascotto A
    Brain Dev; 2006 Jul; 28(6):358-65. PubMed ID: 16376041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two cases of valproic acid poisoning treated with L-carnitine.
    Chan YC; Tse ML; Lau FL
    Hum Exp Toxicol; 2007 Dec; 26(12):967-9. PubMed ID: 18375641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatotoxic effects in a child receiving valproate and carnitine.
    Murphy JV; Groover RV; Hodge C
    J Pediatr; 1993 Aug; 123(2):318-20. PubMed ID: 8345435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of carnitine supplementation in pediatric patients receiving valproic acid therapy.
    Davis D; Farrington E
    Pediatr Nurs; 1992; 18(3):264-5. PubMed ID: 1625956
    [No Abstract]   [Full Text] [Related]  

  • 40. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase.
    Star K; Edwards IR; Choonara I
    PLoS One; 2014; 9(10):e108970. PubMed ID: 25302991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.